SPPL3

SPPL3 is a GxGD-type intramembrane-cleaving aspartyl protease that functions as the principal sheddase for type II membrane-anchored glycosyltransferases and glycosidases in the Golgi, thereby globally regulating protein N-glycosylation, O-glycosylation, and glycosphingolipid biosynthesis (PMID:25354954, PMID:25827571, PMID:35279766). SPPL3 resides predominantly in the mid-Golgi, where it cleaves substrates within their transmembrane domains; cleavage efficiency is governed by substrate-intrinsic features such as transmembrane helix flexibility, with GxxxG motif-containing helices being preferentially processed (PMID:36007678, PMID:36470941). By controlling the glycosphingolipid repertoire—particularly neolacto-series species synthesized by B3GNT5—SPPL3 modulates HLA class I antigen presentation, CD8+ T cell activation, neutrophil trogocytosis, and innate immune killing by NK cells and γδ T cells (PMID:33271119, PMID:39655358). Independent of its protease activity, SPPL3 facilitates STIM1–Orai1 association to promote store-operated Ca²⁺ entry and NFAT activation downstream of T cell receptor engagement (PMID:25384971).

1. 2004 Medium

   Early genetic work in C. elegans showed that the SPP/IMP protease family (including the SPPL3 ortholog) is essential for viability and molting and operates independently of Notch/presenilin signaling, establishing that these GxGD proteases have distinct in vivo functions from γ-secretase.

   Evidence RNAi knockdown and genetic epistasis with Notch components in C. elegans

   PMID:15469912

   Open questions at the time

   • C. elegans ortholog studied (ce-imp-2) is closer to SPP than to SPPL3; direct relevance to mammalian SPPL3 uncertain
   • substrates in worm not identified
2. 2005 High

   Demonstration that mammalian SPPL3 is a catalytically active GxGD-type aspartyl protease whose active-site aspartate is essential for function in vivo, with zebrafish knockdown revealing a requirement for CNS cell survival.

   Evidence Active-site D/A mutagenesis, subcellular localization in cultured cells, antisense knockdown in zebrafish

   PMID:15998642

   Open questions at the time

   • endogenous substrates not yet identified
   • initial localization placed SPPL3 in the ER rather than Golgi
3. 2012 High

   SPPL3 was shown to act as a sheddase capable of cleaving substrates with large ectodomains without prior ectodomain trimming—unlike SPPL2a/b and γ-secretase—establishing a unique proteolytic mode within the GxGD family.

   Evidence In vitro cleavage assay using foamy virus envelope protein and mutant substrates

   PMID:23132852

   Open questions at the time

   • only viral substrate tested; endogenous cellular substrates not yet addressed
   • cleavage site not mapped at residue resolution
4. 2014 High

   Identification of Golgi glycosyltransferases and glycosidases as endogenous SPPL3 substrates resolved the key question of SPPL3's physiological function: it is a master regulator of cellular glycosylation by releasing the catalytic ectodomains of glycan-modifying enzymes.

   Evidence Overexpression and knockdown in cultured cells, biochemical cleavage assays, lectin-based glycosylation profiling

   PMID:25354954

   Open questions at the time

   • substrate repertoire not fully defined
   • mechanism of substrate selectivity unknown
5. 2014 High

   A protease-independent role for SPPL3 was discovered in T cell signaling, where it facilitates STIM1–Orai1 coupling to promote store-operated Ca²⁺ entry and NFAT activation, revealing a non-catalytic scaffolding function.

   Evidence Co-immunoprecipitation of SPPL3 with STIM1/Orai1, Ca²⁺ influx measurements, catalytic-dead mutant retains function

   PMID:25384971

   Open questions at the time

   • structural basis of SPPL3–STIM1 interaction unresolved
   • relevance beyond Jurkat T cells not tested
6. 2015 High

   Systematic secretome proteomics greatly expanded the SPPL3 substrate repertoire to include enzymes of O-glycan and glycosaminoglycan biosynthesis, showing SPPL3's regulatory scope extends well beyond N-glycosylation.

   Evidence SPECS proteomics on SPPL3-deficient and overexpressing cells with biochemical validation

   PMID:25827571

   Open questions at the time

   • not all candidate substrates biochemically validated
   • in vivo confirmation of extended substrate list lacking
7. 2016 High

   In vivo evidence established that SPPL3 protease activity is cell-autonomously required for NK cell maturation and cytotoxicity, linking its catalytic function to immune cell development.

   Evidence Hematopoietic-specific SPPL3 KO and CRISPR knockin of D271A catalytic mutant in mice; in vivo tumor clearance assays

   PMID:26851218

   Open questions at the time

   • whether NK cell defect is glycosylation-dependent or involves additional substrates not determined
   • impact on other immune lineages not fully explored
8. 2020 High

   SPPL3 was identified as a critical regulator of immune recognition: loss of SPPL3 elevates B3GNT5-dependent neolacto-series glycosphingolipids that sterically shield HLA-I from antibodies and TCRs, diminishing CD8⁺ T cell activation.

   Evidence Genome-wide CRISPR screens, GSL profiling, HLA-I antigen presentation and T cell activation assays

   PMID:33271119

   Open questions at the time

   • relevance to in vivo tumor immune evasion not directly shown
   • whether SPPL3 loss also shields other surface receptors via nsGSLs not systematically tested
9. 2022 High

   Endogenous tagging and comprehensive N-terminomics resolved SPPL3's steady-state localization to the mid-Golgi and identified >20 substrates with mapped cleavage sites, establishing that transmembrane domain composition—not mere co-localization—determines cleavage susceptibility.

   Evidence Genome editing for endogenous tagging, TAILS N-terminomics on isogenic KO and D271A knockin lines, chimeric substrate constructs

   PMID:35279766 PMID:36007678

   Open questions at the time

   • no high-resolution structure of SPPL3 or SPPL3–substrate complex available
   • contributions of luminal/cytoplasmic domains to substrate recognition not fully dissected
10. 2022 High

    Biophysical analysis revealed that the GxxxG motif in substrate transmembrane helices promotes helix flexibility that is required for efficient SPPL3-mediated cleavage, providing the first structural rationale for substrate selectivity.

    Evidence Site-directed mutagenesis, hydrogen-deuterium exchange MS, NMR of transmembrane peptides, cleavage assays

    PMID:36470941

    Open questions at the time

    • tested on single substrate (GnTV); generalizability to other substrates not confirmed
    • no SPPL3 active-site structure to visualize helix unwinding during catalysis
11. 2024 Medium

    The immunomodulatory scope of SPPL3 was extended to innate immunity: SPPL3-deficient tumors resist neutrophil trogocytosis and killing by NK cells and γδ T cells, with nsGSL-dependent and -independent mechanisms operating for different effector cell types.

    Evidence SPPL3 KO tumor lines, trogocytosis and cytotoxicity assays with multiple effector cell types, nsGSL inhibition rescue

    PMID:39655358

    Open questions at the time

    • NK cell killing reduction was nsGSL-independent but alternative mechanism not identified
    • in vivo validation in tumor models not reported

• Key open questions include the high-resolution structure of SPPL3 (alone and with substrate), the full in vivo substrate hierarchy in different tissues, whether the protease-independent STIM1–Orai1 scaffolding function is physiologically relevant in primary T cells, and whether SPPL3-controlled glycosphingolipid shielding drives immune evasion in human tumors.
• no cryo-EM or crystal structure of SPPL3
• in vivo substrate hierarchy across tissues unresolved
• protease-independent function not tested in primary cells or in vivo